Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.
Dutasteride is hard to get in Europe due to prescription rules, leading some to consider online pharmacies or travel. Users discuss alternatives like private doctors and compare it to finasteride, expressing concerns about side effects and effectiveness.
The user has been using finasteride for over a year without improvement and recently started oral minoxidil. Suggestions include trying dutasteride and continuing minoxidil for potential regrowth.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
The post and conversation are about a user's one-year progress in treating hair loss. The user used 1 mg of finasteride daily, foam minoxidil once daily, and 1% ketoconazole shampoo 3-4 times a week. The conclusion is that patience and consistency are important in treating hair loss.
Treatments for hair loss, including the effectiveness and safety of Pyrilutamide compared to RU58841; experiences using both medications with varying results; and recommendations to try Pyrilutamide instead of RU58841.
The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Peppermint oil may accelerate hair growth, but its effectiveness for regrowing hair or restoring a receding hairline lacks evidence from human studies or personal experiments. Some online examples exist, but they may be biased by product sales.
A 31-year-old man shares his 4-month hair regrowth progress using topical minoxidil, topical finasteride, microneedling, biotin, and other supplements. He reports new hair growth despite experiencing side effects from finasteride and plans to continue his regimen for further improvement.
The conversation discusses hair loss treatments, with a focus on the use of finasteride, minoxidil, laser treatment helmets, and Redensyl. Opinions vary on the effectiveness and side effects of finasteride, with some users advocating for its use despite potential risks, while others express concerns about its impact on sexual function.
Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
The user reports noticeable hair growth after 5 weeks using finasteride, minoxidil, dermarolling, and ketoconazole. They seek confirmation of their progress and question if they are a hyper responder.
Before getting a hair transplant, it's crucial to research and understand that ongoing treatments like finasteride, dutasteride, or minoxidil are necessary to maintain results. Concerns were raised about Turkish clinics, including overharvesting grafts, lack of regulations, and discouraging finasteride use.
The conversation is about someone starting finasteride (fin) and wondering if it will affect their new ketogenic diet and weightlifting routine, with the goal of not disrupting weight loss or muscle gain while regrowing hair.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A user shared their long-term struggle with hair loss and various treatments, including Minoxidil, biotin, and dermarolling. They also discussed a disappointing experience with a hair health institute that provided dubious recommendations and expensive remedies.
The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.
A 23-year-old man uses a topical spray with minoxidil, finasteride, and tretinoin for hair loss, experiencing improved hair growth but occasional heart palpitations. He worries his girlfriend might leave him if he goes bald, but commenters advise that if she would leave over hair loss, she isn't worth it.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
Transplanted hairs are thinning after switching from topical to oral minoxidil, with increased shedding and miniaturization. The user is considering reintroducing topical minoxidil and has started using ketoconazole shampoo.
Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.